1. Abrahaamson MJ. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med. 2004. 164:486–491.
2. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997. 20:1822–1826.
Article
3. Balflour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1993. 46:1025–1054.
4. Baron AD. Postprandial hyperglycaemia and α-glucosidase inhibitors. Diabetes Res Clin Pract. 1998. 40:S51–S55.
Article
5. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE. IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care. 2000. 23:1236–1241.
Article
6. Campbell RK, White JR, Nomura D. The clinical importance of postprandial hyperglycemia. Diabetes Educ. 2001. 27:624–637.
Article
7. Centers for Disease Control and Prevention. Diabetes Surveillance Report. 1999. Atlanta, GA: US Department of Health and Human Services.
8. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. Diabetes Care. 1995. 18:817–824.
Article
9. Haller H. The clinical importance of postprandial glucose. Diabetes Res Clin Pract. 1998. 40:S43–S49.
Article
10. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999. 22:960–964.
Article
11. Inoue I, Takahashi K, Noji S, Awata T, Negishi K, Katayama S. Acarbose controls postprandial hyper-proinsulinemia in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1997. 36:143–151.
Article
12. Jenkins DJ, Wolever TM, Jenkins AL. Starchy foods and glycemic index. Diabetes Care. 1988. 11:149–159.
Article
13. Jermendy G. Can type 2 diabetes mellitus be considered preventable? Diabetes Res Clin Pract. 2005. 68:S73–S81.
Article
14. Joo HJ, Kang MJ, Seo TJ, Kim HA, Yoo SJ, Lee SK, Lim HJ, Byun BH, Kim JI. The hypoglycemic effect of Saururus chinensis Baill in animal models of diabetes mellitus. Food Science and Biotechnology. 2006. 15:413–417.
15. Kim CH, Kim DI, Kwon CN, Kang SK, Jin UH, Suh SJ, Lee TK, Lee IS.
Euonymus alatus (Thunb.) Sieb induces apoptosis via mitochondrial pathway as prooxidant in human uterine leiomyomal smooth muscle cells. Int J Gynecol Cancer. 2006. 16:843–848.
Article
16. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998. 21:1414–1431.
Article
17. Korea National Statistical Office. The cause of death Statistics 2005. Annual Report of on the Cause of Death Statistics. 2006. Seoul. Republic of Korea: Korea National Statistical Office.
18. Lee H, Kim HK, Ha TY. Antitumor effect of winged Euonymus against chemically induced and malignant cell implanted-tumors in mice. Korean Journal of Immunology. 1993. 15:243–253.
19. Li Y, Wen S, Kota BP, Peng G, Li GQ, Yamahara J, Roufogalis BD.
Punica granatum flower extract, a potent α-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats. J Ethnopharmacol. 2005. 99:239–244.
Article
20. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycemia. Drugs. 1999. 57:19–29.
21. Oh BY, Hwang SK, Cheong MY, Sin HS, Park BH, Lee JH, Kim S. Components and biological activity of aqueous extract isolated from winged stem of Euonymus alatus. Korean Journal of Food Science and Technology. 2005. 37:898–904.
22. Park SH, Ko SK, Chung SH.
Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice. J Ethnopharmacol. 2005. 102:326–335.
Article
23. Saito N, Sakai H, Sekihara H, Yajima Y. Effect of an α-glucosidase inhibitor (voglibose), in combination with sulphonilureas, on glycaemic control in type 2 diabetes subjects. J Int Med Res. 1998. 26:219–232.
Article
24. Sels JP, Huijberts MS, Wolffenbuttel BH. Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother. 1999. 1:149–156.
25. Seo KS, Lim JK, Park JH, Kim CH, Chung GY, Jeong HJ. Antioxidative activity and biological properties in extracts of Euonymus alatus (Thnub.) Sieb. Korean Journal of Life Science. 2003. 13:1–8.
26. Shim YJ, Doo HK, Ahn SY, Kim YS, Seong JK, Park IS, Min BH. Inhibitory effect of aqueous extract from the gall of
Rhus Chinensis on alpha-glucosidase activity and postprandial blood glucose. J Ethnopharmacol. 2003. 85:283–287.
Article
27. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract. 1999. 46:23–27.
Article
28. Stand E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab. 1999. 1:215–220.
Article
29. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in the diabetes control in insulin-dependent diabetes mellitus. N Engl J Med. 1993. 329:977–986.
30. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998. 317:703–713.
31. Watanabe J, Kawabata J, Kurihara H, Niki R. Isolation and identification of -glucosidase inhibitors from Tochu-cha (Encommia ulmoides). Biosci Biotechnol Biochem. 1997. 61:177–178.
Article
32. Youn JY, Park HY, Cho KH. Anti-hyperglycemic activity of Commelina communis L.: inhibition of α-glucosidase. Diabetes Res Clin Pract. 2004. 66S:S149–S155.